Overview

Study of GSK1363089 in Metastatic Gastric Cancer

Status:
Completed

Trial end date:
2009-11-30

Target enrollment:

Participant gender:

Summary

This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in metastatic gastric carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline